Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01230788 · ClinicalTrials.gov registry record · NA
Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia
A NA study, sponsored by Emory University.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT01230788 is a NA study that was terminated before completion, run by Emory University. The registered enrollment target is 1 participants.
The verdict
NCT01230788, a NA study, was terminated before completion, sponsored by Emory University.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a pilot study of a drug called rituximab used together with other drugs-prednisone, etoposide, and ifosfamide. Prednisone, etoposide, and ifosfamide have been used as part of standard chemotherapy for relapsed Acute Lymphoblastic Leukemia (ALL). Rituximab was approved by the Food and Drug Administration in 1997. However, the use of rituximab with prednisone, etoposide, and ifosfamide in pediatric patients with relapsed or refractory ALL is considered experimental. This study is for patients who have ALL in second or greater relapse, or in first relapse and not responding to treatment. The goals of this study are: * To see if using rituximab with prednisone, etoposide, and ifosfamide is beneficial to leukemia treatment * To find out what side effects this combination of drugs can cause A total of 15 participants (30 years old or younger) will be enrolled, over a period of 2 years.
Interventions
- DRUG rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2010-09 |
| Est. Completion | 2012-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01230788
The ClinicalTrials.gov registry entry for NCT01230788 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rituximab is the first listed.
NCT01230788 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01230788 about?
NCT01230788 is a clinical study titled "Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia". This is a pilot study of a drug called rituximab used together with other drugs-prednisone, etoposide, and ifosfamide. Prednisone, etoposide, and ifosfamide have been used as part of standard chemotherapy for relapsed Acute Lymphoblastic Leukemia (ALL). Rituximab was approved by the Food and Drug Ad...
What is the current status of trial NCT01230788?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2010-09. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01230788?
The interventions under investigation include: rituximab (DRUG).
Who is sponsoring clinical trial NCT01230788?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.